Last reviewed · How we verify
Phyllanthus niruri
Phyllanthus niruri is a medicinal plant that exhibits hepatoprotective, anti-inflammatory, and antioxidant properties through multiple phytochemical constituents.
Phyllanthus niruri is a medicinal plant that exhibits hepatoprotective, anti-inflammatory, and antioxidant properties through multiple phytochemical constituents. Used for Liver support and hepatoprotection, Kidney stone prevention and management, Viral hepatitis support.
At a glance
| Generic name | Phyllanthus niruri |
|---|---|
| Also known as | Phyllanthus amarus, Bhumyamalaki, Tamalaki |
| Sponsor | Rosenberg European Academy of Ayurveda |
| Drug class | Herbal/botanical preparation |
| Modality | Small molecule |
| Therapeutic area | Hepatology; Urology |
| Phase | FDA-approved |
Mechanism of action
The plant contains lignans, flavonoids, and other polyphenolic compounds that reduce oxidative stress and inflammation in hepatic tissue. These constituents may inhibit viral replication and support liver function through antioxidant mechanisms. Traditional use suggests benefits in managing liver disorders and kidney stone formation, though the exact molecular targets remain incompletely characterized.
Approved indications
- Liver support and hepatoprotection
- Kidney stone prevention and management
- Viral hepatitis support
Common side effects
- Gastrointestinal upset
- Allergic reactions
Key clinical trials
- Efficacy and Immunomodulator Impact of Herbal Combination on COVID-19 Patients Recovery (NA)
- To Exam the Effects of Phyllanthus Niruri Extracts on Human Neutrophils
- Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease (NA)
- Effect of Polyherbal Formulation in Chronic Inactive Carriers of Hepatitis B Virus (NA)
- A Study of Phyllanthus Niruri and Sida Cordifolia in Diabetic Peripheral Polyneuropathy (NA)
- Complex Imaging Assessment of Steatosis (PHASE4)
- Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Phyllanthus niruri CI brief — competitive landscape report
- Phyllanthus niruri updates RSS · CI watch RSS
- Rosenberg European Academy of Ayurveda portfolio CI